NCT07276100招募中2 期
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- incidence of adverse events of grade > 3
研究概览
简要总结
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy.
Primary Objective:
To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression.
Participants will:
Receive a fecal microbiota transplantation (FMT).
Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form.
- •Age ≥ 18 years.
- •Tolerance to first-line treatment for HCC with atezolizumab plus bevacizumab, defined as absence of adverse events requiring permanent discontinuation of either drug.
- •Ability to comply with all study procedures, in the investigator's judgment.
- •Unresectable hepatocellular carcinoma with early disease progression on first-line atezolizumab + bevacizumab (within 4 months of treatment initiation).
- •At least one untreated measurable lesion per RECIST 1.
- •ECOG Performance Status 0-
- •Child-Pugh class A.
- •Adequate hematologic and end-organ function (laboratory values obtained within 7 days prior to enrollment), defined as follows:
- •ANC ≥ 1.5 × 10⁹/L (1500/µL), without G-CSF support.
- •Lymphocyte count ≥ 0.5 × 10⁹/L (500/µL).
- •Platelet count ≥ 60 × 10⁹/L (60,000/µL), without transfusion.
- •Hemoglobin ≥ 90 g/L (9 g/dL); transfusion allowed if last transfusion ≥ 3 weeks prior.
- •AST, ALT, and ALP ≤ 5 × ULN.
- •Total bilirubin ≤ 3 × ULN.
- •Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
- •Serum albumin ≥ 28 g/L (2.8 g/dL), without infusion supplementation in previous 2 months.
- •INR and aPTT ≤ 1.5 × ULN.
- •Women of childbearing potential:
- •a. Agree to remain abstinent or use effective contraception (failure rate <1%/year) during treatment and for 5 months after last atezolizumab dose and 6 months after last bevacizumab dose.
- •b. Agree to refrain from donating eggs during this period.
- •Men with female partners of childbearing potential:
- •Agree to remain abstinent or use a condom plus an additional contraceptive method (combined failure rate <1%/year) during treatment and for 6 months after last bevacizumab dose.
- •Agree to refrain from donating sperm during this period.
排除标准
- •1. History of leptomeningeal disease or brain metastases.
- •2. Active or prior autoimmune disease or immune deficiency (e.g., myasthenia gravis, myositis, autoimmune hepatitis, SLE, RA, IBD, antiphospholipid syndrome, Wegener, Sjögren, Guillain-Barré, MS), except:
- •Autoimmune hypothyroidism on replacement therapy.
- •Controlled Type 1 diabetes on insulin.
- •Dermatologic-only autoimmune diseases (eczema, psoriasis, lichen simplex chronicus, vitiligo) if:
- •1. Rash <10% BSA.
- •Well-controlled on low-potency topical steroids.
- •No exacerbations requiring systemic therapy within 12 months.
- •3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on CT (radiation pneumonitis in field allowed).
- •4. Active tuberculosis.
- •5. Significant cardiovascular disease within 3 months (NYHA ≥ II, MI, CVA), unstable arrhythmia, or unstable angina.
- •6. Congenital long-QT syndrome or QTcF >500 ms at screening.
- •7. Active advanced malignancy other than HCC within 1 year.
- •8. Prior severe adverse reaction to atezolizumab or bevacizumab unmanageable with low-dose steroids or requiring discontinuation.
- •9. Uncorrectable electrolyte abnormalities (K, Ca, Mg).
- •10. Major surgery within 4 weeks or planned major surgery during study.
- •11. Severe infection within 4 weeks (including hospitalization, bacteremia, severe pneumonia).
- •12. Therapeutic oral/IV antibiotics within 2 weeks (prophylactic antibiotics allowed). All within 30 days has to be recorded in eCRF.
- •13. Prior allogeneic stem cell or solid organ transplantation.
- •14. Any condition or laboratory abnormality posing excessive risk or interfering with study results.
- •15. Live attenuated vaccine within 4 weeks before treatment or planned during or 5 months after atezolizumab.
- •16. Severe allergic or anaphylactic reaction to humanized antibodies or fusion proteins.
- •17. Hypersensitivity to CHO cell products or components of atezolizumab or bevacizumab.
- •18. Pregnancy or breastfeeding; intent to become pregnant during treatment or post-treatment windows.
- •Pregnancy test required within 14 days pre-treatment.
- •19. Fibrolamellar HCC, sarcomatoid HCC, or combined HCC-cholangiocarcinoma.
- •20. Untreated or high-risk esophageal/gastric varices. EGD required; prophylactic treatment mandated.
- •21. Variceal bleeding within 6 months.
- •22. Clinically evident ascites.
- •23. Episode of encephalopathy within 3 months.
- •24. HBV/HCV co-infection.
- •25. Patients with prior HCV but negative HCV RNA are considered non-infected.
- •26. Prior systemic therapy for advanced HCC other than first-line atezolizumab + bevacizumab.
- •27. Systemic immunostimulatory agents (e.g., interferon, IL-2) within 4 weeks or 5 half-lives.
- •28. Symptomatic, untreated, or actively progressing CNS metastases. Eligible only if all criteria are met: extracranial measurable disease, no hemorrhage history, lesions limited to cerebellum/supratentorial region, no progression post-therapy, no recent RT/surgery, no steroid requirement, stable anticonvulsants, new lesions treated before enrollment.
- •29. Uncontrolled tumor-related pain; symptomatic lesions requiring RT must be treated first.
- •30. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring ≥ monthly drainage.
- •Indwelling catheters allowed.
- •31. Uncontrolled or symptomatic hypercalcemia.
- •32. Investigational therapy (other than atezolizumab + bevacizumab) within 28 days.
- •33. Systemic immunosuppressive therapy within 2 weeks, except:
- •Acute, low-dose, or one-time pulse steroids.
- •Mineralocorticoids, inhaled steroids, low-dose steroids for adrenal insufficiency/orthostatic hypotension.
- •34. Uncontrolled hypertension (SBP >150 mmHg and/or DBP >100 mmHg on multiple readings).
- •35. Prior hypertensive crisis or hypertensive encephalopathy.
- •36. Significant vascular disease within 6 months.
- •37. Hemoptysis >2.5 mL within 1 month.
- •38. Bleeding diathesis or significant coagulopathy.
- •39. Current or recent (within 10 days of first dose of study treatment) use of aspirin >325 mg/day or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
- •40. Current or recent (within 10 days prior to study treatment start) use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose. Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR < 1.5 x ULN and aPTT is within normal limits (ratio <1.5) within 14 days prior to initiation of study treatment.
- 另有 12 项未显示
研究组 & 干预措施
experimental
Experimental
Fecal microbiota transplantation (FMT) + atezolizumab (1200 mg flat dose) and bevacizumab (15 mg/kg) Q3W
干预措施: Atezolizumab & Bevacizumab (Drug)
experimental
Experimental
Fecal microbiota transplantation (FMT) + atezolizumab (1200 mg flat dose) and bevacizumab (15 mg/kg) Q3W
干预措施: Fecal microbiota transplantation (FMT) (Other)
结局指标
主要结局
incidence of adverse events of grade > 3
时间窗: through study completion, approximately 3 years
disease control rate
时间窗: 12 weeks after FMT
次要结局
未报告次要终点
研究者
Fabio Piscaglia
Head of Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Clinical Professor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety StatisticsAutism Spectrum DisorderNCT07261826Chen QiYi4,000
尚未招募
不适用
Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant MicroorganismsNCT07265817Kyungpook National University Hospital60
已完成
1 期
Effect of fecal microbita transplantation in treatment of PCOSPoly-cystic ovary syndrome.Polycystic ovarian syndromeE28.2IRCT20190523043674N1Boushehr University of Medical Sciences15
招募中
3 期
Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).Primary Sclerosing Cholangitis2023-505469-95-00Assistance Publique Hopitaux De Paris72
招募中
不适用
The efficacy and safety of faecal microbiota transplantation for recurrent or relapsing Clostridium difficile in Western AustraliaACTRN12615001220550Fiona Stanley Fremantle Hospital Group50